2024-515527-11-00招募中1 期
Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.
ORIC Pharmaceuticals Inc.3 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2025年2月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 48
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Pratik Multani
Scientific
ORIC Pharmaceuticals Inc.
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
2 期
一项评价 BNT327（一种试验药物）与化疗联合治疗既往未接受过治疗的胰腺癌患者的安全性和疗效的临床试验CTR2025479390
招募中
3 期
A study to learn more about how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced non-small cell lung cancer (NSCLC) with mutations of the human epidermal growth factor receptor 2 (HER2)2024-511319-91-00Bayer AG145
招募中
1 期
First-in-Human Study of RO78126532025-522101-37-00F. Hoffmann-La Roche AG12
已完成
2 期
Phase 2 Study of MORAb-202 in Previously Treated Metastatic NSCLC AC2023-504112-15-00Bristol Myers Squibb International Corporation25
进行中（未招募）
1/2 期
A clinical trial to evaluate the safety and effectiveness of a combination of either AG-12or AG-221 tablets with azacitidine injections in patients withnewly diagnosed Acute Myeloid Leukemia (AML) and who have mutations in enzymes isocitrate dehydrogenase 1 or 2 (IDH 1 or IDH2) and are not candidates to receive intensive induction chemotherapy.2024-511722-31-00Celgene Corp.70